Posted by Michael Wonder on 16 Mar 2021
Once again, the viability of the U.S. biosimilar market is thrown into question
15 March 2021 - Despite periodic reports that biosimilars have finally arrived and will save the U.S. health care system billions of dollars, Peter Bach and Mark Trusheim remain unconvinced.
So the high-profile skeptics have refreshed their controversial, two-year-old argument for overhauling the approach for making alternative versions of pricey biologic medicines available to the American public.
